Inhaled micronized crystalline human insulin using a dry powder inhaler: Dose-response and time-action profiles

Diabetic Medicine

Volumn 21, Issue 7, 2004, Pages 763-768

  Rave, K ^a,c   Nosek, L ^a   Heinemann, L ^a   Gonzales, C ^b   Ernest, C S ^b   Chien, J ^b   Muchmore, D ^b  

^a Profil Institute for Metabolic Research   (Germany)

^b ELI LILLY AND COMPANY   (United States)

^c Profil Institute for Metabolic Research   (Germany)

Author keywords

Dose response; Glucose clamp; Inhaled insulin; Pharmacokinetic; Time action

Indexed keywords

IMMUNOREACTIVE INSULIN; RECOMBINANT HUMAN INSULIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG PACKAGING; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN TREATMENT; MALE; NORMAL HUMAN; POWDER INHALER; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VOLUNTEER;

ADMINISTRATION, INHALATION; ADULT; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; CRYSTALLIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; METERED DOSE INHALERS;

EID: 3142702338     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01240.x     Document Type: Article

References (14)

1. Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med 1994; 7: 49-75.
2. Bindra S, Cefalu WT. Alternative approaches to subcutaneous insulin injections. Curr Op Endocr Diabet 2002; 9: 338-341.
3. Owens DR. New horizons - alternative routes for insulin therapy. Nat Rev 2002; 1: 529-540.
4. Laube BL, Georgopoulos A, Adams GK 3rd. Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. JAMA 1993; 269: 2106-2109.
5. Jendle JH, Karlberg BE. Intrapulmonary administration of insulin to healthy volunteers. J Intern Med 1996; 240: 93-98.
6. Heinemann L, Traut T, Heise T. Time-action profile of inhaled insulin. Diabet Med 1997; 14: 63-72.
7. Farr SJ, McElduff A, Mather LE, Okikawa J, Ward ME, Gonda I et al. Pulmonary insulin administration using the AERx (TM) system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabet Tech Ther 2000; 2: 185-197.
8. Heinemann L, Pfutzner A, Heise T. Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des 2001; 7: 1327-1351.
9. Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagatas CC, Cheng S. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001; 357: 331-335.
10. Aftring RP, Gonzales C, Mace K, Phillips E, Chien JY. Time-action and dose-response profiles of inhaled insulin using the Spiros® dry powder inhaler. Diabetologia 2001; 44: A5.
11. Hill M. Characteristics of an active multiple dose dry powder inhaler. In: Byron PR, Dalby RN, Farr SJ, eds. Proceedings of Respiratory Drug Delivery IV, Buffalo Grove, IL: Interpharm Press, 1994, 109-116.
12. Finney DJ, ed. Parallel line assays. In: Statistical Methods in Biological Assays, 3rd edn. London and High Wycombe: Charles Griffin Ltd, 1978: 69-99.
13. Heinemann L, Klappoth WM, Rave KM, Hompesch B, Linkeschowa R, Heise T. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care 2000; 23: 1343-1347.
14. Brunner GA, Baient B, Ellmerer M, Schaupp L, Siebenhofer A, Jendle JH. Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia 2001; 44: 305-308.